Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

AUTL Relative to the S&P 500

AUTL Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Autolus Therapeutics Plc (NASD:AUTL) seasonal charts above shows that a Buy Date of May 11 and a Sell Date of August 7 has resulted in a geometric average return of 17.67% above the benchmark rate of the S&P 500 Total Return Index over the past 7 years. This seasonal timeframe has shown positive results compared to the benchmark in 6 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 7 years by an average of 61.03% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

A word of caution: Only 7 years of data is available for shares of AUTL, perhaps insufficient to create a seasonal profile that accurately gauges the seasonal tendencies influencing the investment. Ideally, while 20 years is preferred, at least 10 years of data is required to perform a seasonal analysis that is considered to be reliable for future seasonal periods.

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

To download AUTL seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: AUTL